利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

844 条记录 (耗时 0.024 秒)

    TREATMENT FOR ALTITUDINAL HYPOXIA
    32.
    发明申请
    TREATMENT FOR ALTITUDINAL HYPOXIA 审中-公开
    治疗高血压

    公开(公告)号：WO2011146471A1

    公开(公告)日：2011-11-24

    申请号：PCT/US2011/036792

    申请日：2011-05-17

    申请人： AESRX LLC ,  SWIFT, Robert, Alan

    发明人： SWIFT, Robert, Alan

    IPC分类号： A61K31/34 ,  A61P11/00 ,  A61P43/00

    CPC分类号： A61K31/34

    摘要： The invention provides a method for treating hypoxia caused by high altitude by administering to a subject a compound that reduces the Ρ 50 of hemoglobin for oxygen.

    摘要翻译： 本发明提供了一种治疗由高海拔引起的缺氧的方法，其通过向受试者施用降低血红蛋白的≥50的氧的化合物。

    VITAMIN C COMPOSITION FOR USE IN THE PREVENTION AND TREATMENT OF STRETCH MARKS, RADIATION DERMATITIS, AND OTHER SKIN CONDITIONS AND METHODS OF USING THE SAME
    33.
    发明申请
    VITAMIN C COMPOSITION FOR USE IN THE PREVENTION AND TREATMENT OF STRETCH MARKS, RADIATION DERMATITIS, AND OTHER SKIN CONDITIONS AND METHODS OF USING THE SAME 审中-公开
    维生素C组合物，用于预防和治疗伸展性商标，放射性皮炎和其他皮肤状况以及使用相同的方法

    公开(公告)号：WO2011085013A3

    公开(公告)日：2011-11-17

    申请号：PCT/US2011020238

    申请日：2011-01-05

    申请人： KAPLAN DAVID L

    发明人： KAPLAN DAVID L

    IPC分类号： A61K31/375 ,  A61K8/67 ,  A61K8/89 ,  A61K47/30 ,  A61P17/00 ,  A61Q19/00

    CPC分类号： A61K8/676 ,  A61K9/0014 ,  A61K31/34 ,  A61K31/341 ,  A61K47/10 ,  A61Q19/004 ,  A61Q19/06

    摘要： A formulation for a stable ascorbic acid composition which, in a simplified form, is comprised of ascorbic acid in solution with a hygroscopic compound (i.e., a substance with the ability to attract water molecules from the surrounding environment through either absorption or adsorption). Also disclosed herein are methods for the production of such compounds and methods of using such compounds in the prevention, inhibition and treatment of striae gravidarum, radiation dermatitis, rhytids, lentigoes, dyschromia, sun-damage induced hyperpigmentation, cellulite, scars and purpura, among other skin diseases or conditions.

    摘要翻译： 用于稳定的抗坏血酸组合物的制剂，其简化形式由抗坏血酸在溶液中与吸湿化合物（即能够通过吸收或吸附从周围环境吸引水分子的物质）组成。 本文还公开了生产这样的化合物的方法以及使用这些化合物预防，抑制和治疗妊娠纹，放射性皮炎，皱纹，扁桃体，色素不足，阳光损伤引起的色素沉着过度，脂肪团，疤痕和紫癜， 其他皮肤疾病或病症。

    SYNERGISTIC EFFECTS BETWEEN SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS AND ANTIMICROTUBULE AGENTS
    38.
    发明申请
    SYNERGISTIC EFFECTS BETWEEN SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS AND ANTIMICROTUBULE AGENTS 审中-公开
    磷脂酸1-磷酸酯受体拮抗剂与抗肿瘤药物之间的协同作用

    公开(公告)号：WO2010045601A2

    公开(公告)日：2010-04-22

    申请号：PCT/US2009/061071

    申请日：2009-10-16

    申请人： EXELIXIS, INC. ,  SHANKAR, Geetha ,  BENTZIEN, Frauke ,  LAMB, Peter ,  MATTHEWS, David

    发明人： SHANKAR, Geetha ,  BENTZIEN, Frauke ,  LAMB, Peter ,  MATTHEWS, David

    IPC分类号： A61K31/16 ,  A61K31/337 ,  A61K31/34 ,  A61K45/06 ,  A61K31/4196 ,  A61K31/435 ,  A61K31/4192 ,  A61P35/00

    CPC分类号： A61K31/4196 ,  A61K31/16 ,  A61K31/337 ,  A61K31/34 ,  A61K31/4192 ,  A61K31/435 ,  A61K2300/00

    摘要： This invention is based on the discovery that the administration of a sphingosine-1- phosphate receptor antagonist (SlP) and at least one chemotherapeutic agent selected from the the group of antimicrotubule agents provides an unexpectedly superior treatment for cancer. Antimicrobial agents such as the taxane compounds are known in the art, for example, paclitaxel (available as TAXOL® from Bristol-Myers Squibb, Princeton, NJ.), docetaxel (available as TAXOTERE® from Sanofi-aventis, Bridgewater, NJ.) and the like and other compounds that act as antimicrotubule agents, such as Vincristine (ONCOVIN®, VINCASAR PFS®, VCR), Vinblastin (VELBAN®, VELSAR®) and Vinorelbine, and similar compounds. The present invention also provides methods of modulating the growth of selected cell populations, such as cancer cells, by administering a therapeutically effective amount of at least one sphingosine-1 -phosphate 1 (SlPlR) receptor antagonists, and at least one antimicrotubule agent.

    摘要翻译： 本发明基于以下发现：施用鞘氨醇-1-磷酸受体拮抗剂（S1P）和选自抗微管剂组的至少一种化学治疗剂提供了出乎意料的优异的癌症治疗。 抗菌剂如紫杉烷化合物是本领域已知的，例如紫杉醇（可从Bristol-Myers Squibb，Princeton，NJ获得），多西紫杉醇（可从Sanofi-aventis，Bridgewater，NJ获得） 和类似物以及用作抗微管剂的其它化合物，例如长春新碱（ONCVIN，VINCASAR PFS，VCR），长春花碱（VELBAN？VELSAR）和长春瑞滨（Vinorelbine）等类似化合物。 本发明还提供了通过施用治疗有效量的至少一种鞘氨醇-1-磷酸1（S1PR1）受体拮抗剂和至少一种抗微管剂来调节所选细胞群体如癌细胞的生长的方法。

    AMINO ALCOHOL DERIVATIVES FOR THE TREATMENT OF DEMYELINATING PERIPHERAL NEUROPATHIES
    39.
    发明申请
    AMINO ALCOHOL DERIVATIVES FOR THE TREATMENT OF DEMYELINATING PERIPHERAL NEUROPATHIES 审中-公开
    用于治疗外周神经病变的氨基醇衍生物

    公开(公告)号：WO2010020609A1

    公开(公告)日：2010-02-25

    申请号：PCT/EP2009/060608

    申请日：2009-08-17

    申请人： NOVARTIS AG ,  LEPPERT, David ,  WALLSTROEM, Erik ,  NUESSLEIN-HILDESHEIM, Barbara

    发明人： LEPPERT, David ,  WALLSTROEM, Erik ,  NUESSLEIN-HILDESHEIM, Barbara

    IPC分类号： A61K31/137 ,  A61K31/16 ,  A61K31/34 ,  A61K31/417 ,  A61K31/42 ,  A61K31/436 ,  A61K31/52 ,  A61K31/56 ,  A61K31/675 ,  A61K38/13 ,  A61K38/21 ,  A61K39/395 ,  A61K45/06 ,  A61P25/00

    CPC分类号： A61K31/137 ,  A61K31/145 ,  A61K31/16 ,  A61K31/34 ,  A61K31/417 ,  A61K31/42 ,  A61K31/436 ,  A61K31/519 ,  A61K31/52 ,  A61K31/56 ,  A61K31/675 ,  A61K38/13 ,  A61K38/21 ,  A61K39/395 ,  A61K45/06 ,  A61K2300/00

    摘要： A compound of formula V or formula Vl for use in the treatment of a demyelinating peripheral neuropathy: wherein X is O, S, SO or SO 2 , R 1 is halogen, trihalomethyl, OH, C 1-7 alkyl, C 1-4 alkoxy, trifluoromethoxy, phenoxy, cyclohexylmethyloxy, pyridylmethoxy, cinnamyloxy, naphthylmethoxy, phenoxymethyl, CH 2 -OH, CH 2 -CH 2 -OH, C 1-4 alkylthio, C 1-4 alkylsulfinyl, C 1-4 alkylsulfonyl, benzylthio, acetyl, nitro or cyano, or phenyl, phenylC 1-4 alkyl or phenyl-C 1-4 alkoxy each phenyl group thereof being optionally substituted by halogen, CF 3 , C 1-4 alkyl or C 1-4 alkoxy; R 2 is H, halogen, trihalomethyl, C 1-4 alkoxy, C 1-7 alkyl, phenethyl or benzyloxy; R 3 is H, halogen, CF 3 , OH, C 1-7 alkyl, C 1-4 alkoxy, benzyloxy, phenyl or CMalkoxymethyl; each of R 4 and R 5 , independently is H or a residue of formula (a),wherein each of R 8 and R 9 , independently, is H or C 1-4 alkyl optionally substituted by halogen; and n is an integer from 1 to 4; and the N-oxide derivatives thereof or prodrugs thereof, or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein R 1a is halogen, trihalomethyl, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkylthio, C 1-4 alkylsulifinyl, C 1-4 alkyl-sulfonyl, aralkyl, optionally substituted phenoxy or aralkyloxy; R 2a is H, halogen, trihalomethyl, C 1-4 alkyl, C 1-4 alkoxy, aralkyl or aralkyloxy; R 3a is H, halogen, CF 3 , C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkylthio or benzyloxy; R 4a is H, C 1-4 alkyl, phenyl, optionally substituted benzyl or benzoyl, or lower aliphatic C 1-5 acyl; R 5a is H, monohalomethyl, C 1-4 alkyl, C 1-4 alkoxy-methyl, C 1-4 alkyl-thiomethyl, hydroxyethyl, hydroxypropyl, phenyl, araikyl, C 2-4 alkenyl or -alkynyl; R 6a is H or C 1-4 alkyl; R 7a is H, C 1-4 alkyl or a residue of formula (a) as defined above, X 3 is O, S, SO or SO2; n a is an integer of 1 to 4; and designates a chiral centre of (R) or (S) configuration and the formula includes racemic and other mixtures of (R) and (S) configuration molecules; and the N-oxide derivatives thereof or prodrugs thereof, or a pharmaceutically acceptable salt, solvate or hydrate thereof.

    摘要翻译： 用于治疗脱髓鞘性周围神经病变的式V或式VI化合物：其中X是O，S，SO或SO 2，R 1是卤素，三卤甲基，OH，C 1-7烷基，C 1-4烷氧基，三氟甲氧基，苯氧基， 环己基甲氧基，吡啶基甲氧基，肉桂氧基，萘基甲氧基，苯氧基甲基，CH2-OH，CH2-CH2-OH，C1-4烷硫基，C1-4烷基亚磺酰基，C1-4烷基磺酰基，苄硫基，乙酰基，硝基或氰基，或苯基，苯基C1-4烷基或苯基C1- -4-烷氧基，其各个苯基任选被卤素，CF 3，C 1-4烷基或C 1-4烷氧基取代; R2是H，卤素，三卤甲基，C1-4烷氧基，C1-7烷基，苯乙基或苄氧基; R 3是H，卤素，CF 3，OH，C 1-7烷基，C 1-4烷氧基，苄氧基，苯基或C 1烷氧基甲基; R 4和R 5各自独立地是H或式（a）的残基，其中R 8和R 9各自独立地是H或任选被卤素取代的C 1-4烷基; n为1〜4的整数。 和其N-氧化物衍生物或其前药，或其药学上可接受的盐，溶剂化物或水合物，其中R 1a为卤素，三卤代甲基，C 1-4烷基，C 1-4烷氧基，C 1-4烷硫基，C 1-4烷基磺酰基，C 1-4烷基磺酰基 ，芳烷基，任选取代的苯氧基或芳烷氧基; R 2a是H，卤素，三卤甲基，C 1-4烷基，C 1-4烷氧基，芳烷基或芳烷氧基; R3a是H，卤素，CF3，C1-4烷基，C1-4烷氧基，C1-4烷硫基或苄氧基; R 4a是H，C 1-4烷基，苯基，任选取代的苄基或苯甲酰基，或低级脂族C 1-5酰基; R5a为H，单卤甲基，C1-4烷基，C1-4烷氧基甲基，C1-4烷基硫代甲基，羟乙基，羟丙基，苯基，芳烷基，C2-4烯基或 - 炔基; R 6a是H或C 1-4烷基; R 7a是H，C 1-4烷基或如上定义的式（a）的残基，X 3是O，S，SO或SO 2; na为1〜4的整数， 并且表示（R）或（S）构型的手性中心，并且该式包括（R）和（S）构型分子的外消旋和其它混合物; 及其N-氧化物衍生物或其前药，或其药学上可接受的盐，溶剂合物或水合物。